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Abstract 
In this Major Qualifying Project (MQP), the transport mechanism in Taxus cell culture was 
investigated with the intent to optimize the downstream process of paclitaxel production. 
Bioinformatics analysis, inhibitor testing and investigation of an alternative method of paclitaxel 
quantification were conducted as part of the research. A homolog to the mammalian MDR protein 
in Taxus cells was identified for its potential to transport paclitaxel in Taxus cells. The transport 
mechanism was also studied using transport protein inhibitors, and results show that the 
concentration of verapamil affects the direction of paclitaxel transport. To simplify the 
investigation process, Uv-vis spectroscopy was studied as a potential substitution for UPLC to 
quantify paclitaxel; however, since Gamborg B5, a standard component in cell media, interferes 
with the assay, Uv-vis spectroscopy cannot be used as a quantification substitution. Future studies 
based on the investigation routes in this project can be conducted to maximizing the concentration 
of paclitaxel in the media via extracellular secretion and simplifying steps in the paclitaxel 
separation and purification process. 
1. Background 
1.1 Introduction of Paclitaxel 
Paclitaxel (Taxol™) is a specialized metabolite, produced by the Pacific Yew tree, Taxus 
brevifolia, and largely stored in the tree bark (1). Paclitaxel is a FDA approved anticancer drug 
that has been widely used in different cancer treatments.  
Paclitaxel induces cellular apoptosis by acting as a microtubule-stabilizing agent. Studies 
have found that paclitaxel can interact with the beta subunit of tubulin, which prevents the 
disassembly of microtubules (2). When paclitaxel is present in the cells, chromosomes are unable 
to separate during mitosis in metaphase, forcing the cells to enter the stage of mitotic arrest and 
triggering apoptosis. Unlike other chemotherapeutic drugs that inhibit microtubule assembly, 
paclitaxel induces defects in mitotic spindle assemble, chromosome segregation and cell division 
(4,5,6,7). This cell killing mechanism makes paclitaxel unique among chemotherapeutic agents. 
Paclitaxel is used to treat breast, ovarian, lung, bladder, prostate, melanoma, esophageal 
and other types of cancers and tumors (3). It is given through an injection or infusion into the vein 
(Intravenous, IV). In other delivery strategies, paclitaxel is combined with a protein called albumin; 
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this combination is used to treat breast cancer and pancreatic cancer that has spread. The market 
name of this drug combination is “Abraxame” and it has proven to have reduced side effects on 
patients (8). 
Paclitaxel by itself as a chemotherapy agent and as a pill used in combination with proteins 
has shown to be an effective method of treating different types of cancer. Cancer is a disease that 
the National Cancer Institute estimates will have 1,685,210 new cases in 2016. The fact that the 
disease affects such a high percentage of the world’s population indicates that the demand for anti-
cancer agents such as paclitaxel is going to increase as its effectiveness against other cancers are 
uncovered. Full optimization of the drug production will highly benefit future patients due to 
market availability of the product. 
1.2 Chemical structure 
The chemical name of paclitaxel is 5β, 20-epoxy-1,2α,4, 7β,10β,13α-hexahydroxytax-11-
en-9-one4, 10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine. It is a 
complex diterpene with a taxane ring system linked to a four-membered oxetane ring at positions 
C4 and C5 and an ester side chain at C13 (Figure 1). Paclitaxel chemical formula is C47H51O14, 
and its molecular weight is 853.906g/mol. It is a stable compound incompatible with strong 
oxidizing agents and combustibles. The melting point of paclitaxel is 213-216 °C (9). 
Due to the multiple hydrocarbon rings in the structure, paclitaxel is a hydrophobic molecule. It can 
be dissolved in the organic solvents, such as methanol, DMSO and acetonitrile, but is insoluble in 
water (10). The solubility of paclitaxel in methanol is 50 mg/mL (11).  Due to its hydrophobicity, 
paclitaxel can diffuse through the lipid bilayer membranes from extracellular to intercellular 
compartments in the mammalian cells (12). However, in the plant cells, beside the diffusion, 
studies had indicated paclitaxel is in part transported by a specific mechanism such as a channel 
membrane protein or a cell surface receptor. Further detail studies have to be done in order to fully 
understand the paclitaxel transport system (40). 
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Figure 1: Paclitaxel Organic Structure (D) (13) 
 
1.3 History of discovery of paclitaxel 
Paclitaxel was discovered in 1962, through the National Cancer Institute (NCI) plant-
screening program explain the goal of this screening (1), As a result of this screening, paclitaxel 
was found to be cytotoxic and investigators were able to isolate the active ingredients from the 
crude extract of the bark of the tree. Later experiments reported that the molecule had antitumor 
activity (14). 
In 1971 Dr. Horwitz at the Albert Einstein College of Medicine in the Bronx, New York 
concluded that paclitaxel is able to completely inhibit the division of exponentially growing cells 
at low drug concentrations without interfering with DNA or RNA. In this study, the drug was 
found to prevent cell growth by interfering with mitosis (2), as described above. 
Paclitaxel was further used as an anti-cancer treatment in clinical trials; however progress 
was severely limited by the shortage of paclitaxel. The high demand of paclitaxel spurred further 
investigation into sustainable production methods. Historically, paclitaxel has been successfully 
produced by four different methods, three of which are not currently used due to their complexity 
along with and negative social and environmental impacts. Table 1 summarizes the advantages 
and disadvantages of all of the production methods. 
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Production Method Advantages Disadvantages 
 
Crude Bark Extraction 
• Easiest method to extract 
paclitaxel 
• No need of harsh 
solvents 
• No expensive machinery 
needed for extraction 
• Environmentally 
unfriendly 
• Low yield 
• Not year-long production 
 
Total Organic Synthesis • Environmentally friendly 
• Year-round production 
 
• Use of harsh solvents  
• Just 2% percent paclitaxel 
yield 
• Many steps 
Semi-Organic Synthesis • Precursors can be 
extracted without killing 
the tree 
• Year-round production  
• Use of harsh solvents  
• Low percent paclitaxel 
yield 
• Many steps 
• Need extraction of 
precursors  
Plant Cell Culture • No use of harsh solvents  
• Higher yield percent  
• Relatively cheap 
components for medium 
• No high land 
requirements  
• Manipulated system 
• Economically friendly 
• Environmentally 
friendly 
• Year-round production 
• Not fully  
• Unknown biosynthesis 
pathway 
• Not every cell in culture is 
producing paclitaxel 
• Not fully understood 
Paclitaxel transport 
mechanism 
 
 
Table 1. The advantages and disadvantages of paclitaxel production methods 
 
1.4 Paclitaxel production methods  
1.4.1 Crude extraction as a paclitaxel production method 
Crude extraction has been done on the bark of the yew trees. Paclitaxel has been extracted 
from the bark and needles of various yew species by ordinary solvent extraction (OSE) (15). This 
extraction works by partially removing a substance from a solution or mixture by dissolving it in 
another immiscible solvent in which it is more soluble (16). The majority of OSE processes 
reported to use methanol as the extraction solvent at room temperature. 
Many issues are associated with crude extraction method. First, the growth cycle of yew tree 
is long and the tree also rarely exceeds 60 cm (24 in) in diameter and 15 m (49 ft) in (17). Studies 
indicate that the tree should be around 100 years old to be fully ready for paclitaxel extraction. 
Therefore, the production via crude extraction has a high land requirement for the growth of the 
trees with very low yields (18).  
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Moreover, crude extraction is extremely environmentally unfriendly, because the bark 
stripping process requires sacrifice of the tree. For example, in the first conducted clinical trial, the 
NCI acquired 27,700 kg (60,000 lb) of dried Pacific Yew bark. However, from the 27,700 kg of 
dried bark, only 4 kg (9 lb) of dry and crystalline paclitaxel was extracted (19). The total amount 
of extracted paclitaxel was not even enough to complete the first phase of the clinical trials. This 
unusable low yield of the paclitaxel makes the crude extraction an environmental and economically 
unfeasible production method.    
It is important to highlight that the bark of three mature 100-year-old trees provides only 1 
gram of paclitaxel, and the amount needed for a course of the treatment of one patient is 2 grams 
(20). The shortage of paclitaxel from natural harvest led researchers to investigate alternative 
production pathways for the drug.  
14.2 Total synthesis of paclitaxel  
Another way of producing paclitaxel is through total organic synthesis. There have been 
numerous attempts to synthesis the drug. Thirty different groups and labs were working on the 
synthetic process, however most of them fell short due to paclitaxel’s complex structure. Until 
1994, Nicolaou and his group from UC San Diego and The Scripps Research Institute, and Holton 
and his group from Florida State University, independently published the first total syntheses 
of paclitaxel using different starting compounds (21, 22). 
 
Figure 2. Nicolaus semi-sythensis C ring creation (23) 
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Figure 2 represents the ring synthesis steps of creating paclitaxel by the synthesis of ring C 
published used by Nicolaou’s group. Nicolaou’s synthesis was considered convergent since the final 
molecule is assembled from 3- preassemble synthons. Cyclohexene ring C is one of the two major 
parts of his synthesis. Even though total synthesis is possible, the complexity of the structure requires 
multiple synthesizing steps, toxic and harsh chemicals. In addition, the overall paclitaxel yield from total 
synthesis is low. These factors make the total syntheses production methods not economically to provide 
for the large scale-pharmaceutical demand.  
1.4.3 Semi-synthesis of paclitaxel 
The semi-synthesis method was the sole large-scale industrial method for some time. It was 
found that the Pacific Yew tree contained a wide range of diterpenoid derivative taxanes, which 
are structurally similar to paclitaxel. Paclitaxel is a member of a small group of compounds 
possessing a four membered oxetane ring and a complex ester side-chain in their structure, both of 
which are essential for antitumor activity. The amount of other paclitaxel precursors that can be 
extracted from the tree through the bark or needles is considerably higher than paclitaxel. Every 
part of the Pacific Yew tree contains much more baccatin III, 10-deacetyltaxol, 10-
deacetylbaccatin III, cephalomannine and 10-deacetylcephalomannine. Therefore, it is much more 
promising to produce paclitaxel using these more ubiquitous precursors, since they can be 
recovered from collecting only needles. Baccatin III and 10-deacetylbaccatin III (Figure 3) have 
been extracted and used as precursors from which to initiate paclitaxel synthesis in the laboratory. 
They have been efficiently transformed into paclitaxel though chemical semi-synthesis (24). The 
semi-synthesis process requires harsh solvents and reactions, again leading investigators to find 
more sustainable alternative production methods.  
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Figure 3. Baccatin III and 10-deacetylbaccatin III precursor for paclitaxel semi-synthesis (25) 
 
1.4.4 Plant cell culture 
 Although the semi-synthesis method of paclitaxel was used in the industry, plant cell 
culture is currently the main production method of paclitaxel (26). Bristol-Myers Squibb (BMS) 
patented the commercialization of the compound and introduced it to the market as Taxol™. They 
held the contract to harvest the bark; however due through their partnership with the company 
Phyton (Germany) they now produce paclitaxel solely using the plant cell culture process the 
company developed. Current paclitaxel production comes from multiple sources, since even 
though BMS held the original paclitaxel license, now there are multiple generic producers (27). 
Plant cell culture is preferred in the industry because it is a continuous, sustainable and 
high yielding method. As mentioned previously, the growth rate of yew tree is slow and the crude 
extraction requires sacrificing trees due to bark stripping.  Comparing with the synthetic methods, 
plant culture uses more mild chemicals and the process is more environmentally friendly. In plant 
cell culture, there is also less chance of harboring human pathogens and producing endotoxins (28).    
Even though the method of plant cell culture is preferred and currently used to supply 
paclitaxel commercially, there are many knowledge gaps that exist in the process. Much more 
scientific research is needed to understand and optimize the production process of paclitaxel. 
Currently most paclitaxel producing cell lines have been demonstrated to release as little as 7–
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10% of the total paclitaxel produced to the extracellular medium (29). Further studies have 
suggested that most of the paclitaxel is bound to the cell walls and therefore remains associated 
with the cell. The lack of release of paclitaxel to the extracellular medium requires that a complex 
purification process is needed to obtain high yield of paclitaxel from culture. The separation 
process includes the steps such as product removal from media and/or culture broth, isolation using 
an organic solvent, crude purification and final purification.   
 Cell culture Disruption/ 
Filtration 
LLE Evaporation- 
crystallization 
Chromatography 
Equipment/ 
Supplies 
Bioreactor, 
cells, nutrients, 
oxygen 
Physical 
agitator or 
sonicator 
Extraction unit, 
solvent 
Vacuum 
crystallizer 
Normal phase or 
reversed-phase 
column, solvent 
Major Costs Sterilization, 
equipment 
Filtration 
equipment, 
energy 
Solvent 
recovery and 
make-up 
Equipment, 
energy 
Equipment, labor, 
solvent 
Fractional 
recovery  
N/A 85-95% 80-90% 75-90% 75-85% 
Purity weight  0.001-0.04% 0.1-0.5% 1-4% 60-75% 98.5-99.5% 
Table 2. sequence of process steps for paclitaxel separation at large-scale (30) 
 
Specific steps that are needed for a large-scale separation of paclitaxel are shown in Table 2. 
Multiple steps are needed to achieve a high recovery of paclitaxel. However, the number of 
purification steps can be reduced through a better understanding of the production and transport 
mechanism of paclitaxel in Taxus cultures. In other words, paclitaxel production can be optimized 
by further investigating the biosynthesis pathway of paclitaxel, also studying its transport 
mechanism to extracellular compartment and its distribution in the media.  
2. Introduction of the Major Qualifying Project 
The purpose of this Major Qualifying Project (MQP) is to study the transport mechanism 
of paclitaxel in Taxus cell culture with the intent to optimize the downstream process of paclitaxel 
recovery and purification. Particularly, the ultimate goal of this research is to maximize the 
concentration of paclitaxel in the media via extracellular secretion to eliminate steps in the 
production process. 
This MQP consists of three sections: bioinformatics analysis, inhibitor testing and 
development of an alternative quantification method for paclitaxel. In the first section, the 
objective was to identify a homolog to the mammalian MDR protein in Taxus cells. A protein 
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candidate, E6Y0T0, was identified. However, its expression in the current Taxus cell lines and 
under paclitaxel producing conditions needs further study. In the second section, the objective was 
to study the transport mechanism through the use of transport protein inhibitors. Four different 
inhibitors were used and experimental results show that the concentration of verapamil affects the 
direction of paclitaxel transport. Finally, the third objective of this project was to develop an 
alternative method of quantifying paclitaxel to simplify this investigation process. Uv-vis 
spectroscopy was investigated as a potential substitution; however, Gamborg B5 in the media was 
identified as an interfering compound in the Uv-vis assay complicating quantification and 
necessitating the use of Ultra High Performance Liquid Chromatography (UPLC) in paclitaxel 
quantification 
3. Methodology and experimental setup 
3.1 Bioinformatics analysis 
3.1.1 Literature reviews 
Although the paclitaxel transport mechanism is not yet fully understood, research has 
provided information on specialized metabolite transport in both mammalian and plant systems. 
In mammalian cells, one group of proteins called multidrug resistant (MDR) proteins is responsible 
for anti-cancer drug efflux. This group of proteins belongs to the B subfamily of the ATP binding 
cassette (ABC) proteins. ABCB1 (MDR1) is the best studied protein in the group (31). MDR 
proteins are responsible for the extracellular transport of hydrophobic chemotherapeutic drugs in 
mammalian cells. Overexpression of these transporters is one of the drug resistance mechanisms 
used by cancer cells (31, 32). Therefore, the genetic sequences, structures and transport 
mechanisms of MDR proteins are well characterized. The crystal structure of ABCB1, which is 
known to transport paclitaxel as a substrate in mammalian cells, has been determined (33, 34) 
(Figure 4).  
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A)  B)  
Figure 4. A. Crystal structure of ABCB1 protein; B. Proposed transport mechanism of ABCB1 (34) 
 
An example of well-studied plant specialized metabolite transporter is a MDR-type protein, 
CjMDR1, in Coptis japonica. It is responsible for uptake of berberine, a specialized metabolite, 
into rhizome cells. Similar to the MDR protein in mammalian cells, CjMDR1 is located in the 
plasma membrane (35). The proposed structure and transport function of CjMDR1 has been 
suggested (Figure 5). Its transport mechanism has been studied by using potential inhibitors to 
suppress the function of transport protein and correlation with berberine concentrations in different 
compartments. The gene was cloned using homology-based RT-PCR, and the function of the 
CjMDR1 was then characterized by transforming the genes into Xenopus oocytes (36, 37).  
 
      Figure 5. Proposed structure and transport function of CjMDR1 protein and a picture of Coptis japonica (35). 
 
Both cases above demonstrate that MDR proteins are responsible for specialized metabolite 
transport in mammalian and plant systems. The sequences and functions of ABC proteins are 
highly conserved across a wide range of eukaryote species (38). Therefore, it is hypothesized that 
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a MDR-type protein in Taxus is responsible for paclitaxel transport. Past research suggests that a 
specific active transport mechanism exists in Taxus cells since the paclitaxel can be transported 
against a concentration gradient and this process is dependent on calcium ion concentration (39, 
40). 
3.1.2 Identification of the homolog protein in Taxus cells  
Research has shown that ABCB1 and ABCB4 MDR proteins are responsible for paclitaxel 
efflux in mammalian cells (41). The protein sequences of these two proteins were obtained from 
the National Center for Biotechnology Information (NCBI) database. Since the function of a 
protein is determined by its protein sequence, the protein sequence of a protein with homologous 
function in Taxus should be similar to that of MDR proteins in mammalian cells. In order to 
identify a protein with high similarity to the known MDR proteins in mammalian cells, the 
database was searched against the known sequences of ABCB1 and ABCB4. Protein sequences 
are considered identical if aligning amino acids in the sequences are exactly the same. When 
corresponding amino acids in the sequences are not the same but have similar chemical properties, 
such as leucine and valine, the sequences are considered similar to each other (42). The more 
identical or similar amino acids exist in the sequence of interest, the higher percentage of identity 
or similarity of that sequence comparing with the known sequences. The generally accepted rule 
is that two sequences need to have at least 30% identity to be considered as homologs (43). 
Therefore, the search results were sieved with a 30% identity threshold to be considered as 
homologs. Once a protein candidate was identified from the Taxus transcriptome (available in the 
Roberts laboratory), its protein sequence was aligned with the sequences of known MDR proteins 
on the NCBI website by using the align function. The similarity and identity of the sequences in 
the functional domains were also obtained from the website to further confirm the similar function 
of the MDR protein and the protein candidate. The complete proteins sequences and alignments 
are included in Appendix A and B.  
3.1.3 Confirmation of the protein candidate existence in Taxus cell cultures  
After identifying the protein candidate in the database, the existence of the protein 
candidate sequence in the genome of current Taxus cell cultures maintained in the Roberts 
laboratory was studied via polymerase chain reaction (PCR) on the DNA extracts of all the Taxus 
cell lines available. The goal was to amplify the gene through PCR and visualize a band through 
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gel electrophoresis of the expected length; these data would suggest the gene sequence was present 
in the genome of the cell lines. Because the Taxus genome has not yet been sequenced, only the 
transcriptomic data of E6Y0T0 was available (included in Appendix C); therefore, primers were 
designed based on the mRNA sequence of the protein candidate from the NCBI Primer-Blast 
website. A PCR product size in the range of 3000 to 4500 bp was expected because the length of 
the mRNA is about 3900 bp. The minimum, maximum and optimum primer melting temperatures 
were set to 57 °C, 63 °C and 60 °C respectively. Ten pairs of primers were designed. The melting 
temperature, possibility of self-dimerization and hairpin formation, and Gibbs free energy of the 
primers were considered through assistance of the Technical Support Department of Integrated 
DNA Technologies (IDT). Primers that can be used in the PCR reaction should have melting point 
below 65 °C, low possibility of formation self-dimerization and hairpin, and Gibbs Free Energy 
no negative than -9 kcal/mol (44). The pair of primer that best fits these requirements was 
suggested by the Technical Support Department, which is, was used for the PCR experiment. The 
time and temperature cycle of the reaction in the thermo cycler was set as shown in Figure 6. 
A)  
B)  
Figure 6. The thermocycles of PCR reactions using A) Taq and B) Q5 polymerase 
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Two different DNA polymerases, Q5 and Taq, were used in the reaction. Although Taq is 
one of the most common DNA polymerases used, Q5 is a more robust DNA polymerase since it 
has about 280 times higher fidelity than Taq. In other words, the amplicons will be more accurate 
when Q5 is used in the PCR (45, 46). To ensure the target gene could be amplified and the gene 
identification in the cells would not be influenced by the robustness of DNA polymerase, both Q5 
and Taq were tested. Two extension times, 4 min and 6 min, were used to make sure the gene was 
fully amplified despite the long product length. DNA extraction of Taxus cell lines P93AF, C093D, 
P093XC and 21260C, and Arabidopsis cells (as a negative control) was performed following the 
instructions of the DNeasy® Plant Mini Kit from Qiagen. Among these cells lines, only 21260C 
is currently accumulating paclitaxel. Arabidopsis, one of the model organisms for plant research, 
was used as a negative control in the test. Agarose electrophoresis was used to visualize the PCR 
product. Agarose gels were made and used along with the DNA ladder O’RangeRuler 200 bp from 
Thermo Scientific to confirm the band size. SYBR Safe, a DNA gel stain from Thermo Fisher 
Scientific, was added to the gels for DNA visualization. The gels were run at 110 volts for 40 
minutes. The results were captured under UV light.  
3.2 Inhibition of active transport 
3.2.1 Literature review: inhibitors selection 
To better understand MDR proteins, the cancer researchers have studied inhibition of the 
transport mechanism to develop a solution for drug resistance. Verapamil has been identified as 
an inhibitor for ABCB1 and other MDR proteins for its activity as a calcium pump blocker (47). 
It has been used block the efflux of paclitaxel in mammalian cells (39). The binding sites of 
verapamil in ABCB1 have been identified as Leucine (Leu) 65, Isoleucine (Ile) 306, Isoleucine 
(Ile) 340, and Phenylalanine (Phe) 343 (shown in Figure 7).  
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Figure 7. The binding site of verapamil in ABCB1 protein (38).  
 
Since verapamil inhibits paclitaxel efflux via MDR proteins from mammalian cells (38), it could 
also inhibit the transport of paclitaxel in Taxus cells. Similar to verapamil, cyclosporine A has also 
shown inhibition of transport of specialized metabolites in the studies of berberine. According to 
the studies, cyclosporine A can inhibit the uptake of berberine by rhizome cells (48). It is a known 
inhibitor for ABCB1 protein and it most likely inhibit the protein function by blocking the transport 
pathway (49). Therefore, it is also a good inhibitor candidate for the MDR-type transport protein 
in plant cells, especially in Taxus cells. Moreover, since the MDR proteins belong to the ABC 
transport protein family, the activities of MDR proteins are dependent on ATP consumption. 
Theoretically, the activity of the MDR proteins should be inhibited by the ATPase inhibitors 
although the side effects on other cellular ATP-dependent activities should be considered. 
Vanadate, a potent inhibitor of ATPase, therefore, may affect the paclitaxel transport mechanism 
of a potential MDR-type transport protein in Taxus cells (39). In addition to inhibitors of MDR 
proteins, scientists also identified inhibitors for non-MDR proteins in the ABC protein family. 
Genistein, an inhibitor of the proteins in ABCG subfamily, is one example (50). It could inhibit 
tyrosine autophosphorylation, which is used in ABCG protein action (51).  
All four inhibitors mentioned were used to investigate paclitaxel transport in Taxus in this 
project. Verapamil, cyclosporine A, and vanadate were used to investigate the transport 
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mechanism by inhibiting the activity of the potential MDR-type protein. Genistein, however, was 
used as a negative control in the experiment. In other words, since it is an inhibitor of ABCG 
protein that does not belong to the MDR proteins family, paclitaxel transport should not be affected 
when genistein is used. When the Verapamil, cyclosporine A, and vanadate are incubated with 
Taxus cells individually, the concentration of the paclitaxel in the media and cells should be 
different than that in the cell culture without the inhibitor treatment. However, when genistein is 
incubated with the cells, the concentration of paclitaxel inside or outside of the cells should be 
comparable with the cell culture that does not have the inhibitor treatment. In general,  the 
paclitaxel uptake was been inhibited if the concentration of paclitaxel in the media is higher in 
media and lower in cells with than that in the culture without the treatments. If the reverse is true, 
then the paclitaxel uptake was been facilitated.  
3.2.2 Cell viability test in the presence of the selected inhibitors 
 A cell viability test with the inhibitors (verapamil, cyclosporine A, and genistein), the 
paclitaxel delivery solvent (methanol) and the cyclosporine A and genistein delivery solvent 
(DMSO) was performed to determine whether the compounds and solvents would compromise 
cell viability. 12.5 µl of 100 mM inhibitors solutions were added to 10 mL Taxus cell cultures in 
25 ml flasks and incubated for 48 hours. The final concentration of the inhibitors in the cell culture 
was 125 µM. The viability of cells was tested twice: after 24 hours incubation and after 48 hours 
incubation. 1 mL of cell with media samples were taken at each time point. 10 µl of 0.5 mg/mL 
Fluorescent diacetate (FDA) and 5 µl of 0.1 mg/mL propidium iodide (PI) were added into each 
cell culture sample and used as indicators for cell viability and death respectively. If the cells are 
alive, non-fluorescent FDA would be converted to fluorescein with green fluorescence (52). If the 
cells are dead, the PI would be able to permeate the cell membranes and stain the nuclei with red 
fluorescence.  Fluorescent microscopy was used to visualize the cells with the stains by using an 
absorbance at 494 nm and emission at 520 nm to identify alive cells and an absorbance of 536 nm 
and emission at 617 nm to identify dead cells. The culture viability was quantified by estimating 
the percentage of the live and dead cells through a quick visualization test. 
3.2.3 Initial inhibitor test 
3.2.3.1 Experimental setup 
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After confirming the effect of the inhibitors and solvents on the viability of cells, we tested 
all of the inhibitors to determine if they influence paclitaxel transport. Two final concentrations of 
inhibitors were added to the culture: 50 µM and 100 µM of verapamil, cyclosporine A and 
genistein in DMSO and 1 mM and 0.5 mM of vanadate in water. Each inhibitor solution was added 
to 15 mL P093X line Taxus cell culture at day 7 and pre-incubated for 1 hour. There are triplicates 
for each inhibitor treatment. Paclitaxel was then dissolved in methanol added after pre-incubation 
at a final concentration of 8.3 mg/L, and the volume percentage of methanol in the cell culture is 
about 0.3%. The cells, inhibitor, and paclitaxel were incubated and sampled at 1.5, 3, 6 and 24 
hours. For each time point, 1 mL of total culture was sampled along with 1 mL of liquid media.  
3.2.3.2 Sample processing for UPLC analysis 
The cell and media only samples were processed to be tested via UPLC for paclitaxel 
quantification. The processing procedure is shown in Figure 8. 
 
Figure 8: Inhibitor Sample Methodology. CE stands for centrifugal evaporator. 
 
 Cell samples were washed with nanopure water and the media samples were centrifuged 
to isolate the supernatant in 1.5 mL micro-centrifuge tube and remove all particulates. Both cell 
and media samples were dried in the centrifugal evaporator overnight and re-suspended in 1 mL 
of methanol. After being sonicated in an ice bath for 30 minutes to make sure the dry pellet was 
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dissolved in the methanol, the samples were centrifuged at 132,000 rpm for 20 minutes to obtain 
the supernatants. The supernatants were transferred to fresh 1.5 mL micro-centrifuge tubes and put 
into the centrifuge evaporator again for six hours. All the samples were re-suspended again in 
70:30 water: acetonitrile solution. The samples were then filtered through a 0.22 µm filter directly 
into the UPLC glass vials. The vials were placed into the UPLC and the concentration of paclitaxel 
in the samples were quantified using a standard curve generated with varying levels of paclitaxel 
in the same UPLC run. 
3.2.4 Investigation of the effect of concentration on inhibition  
To further investigate the effect of inhibitor concentration on paclitaxel transport, we added 
verapamil to P093X Taxus cell cultures at a higher concentration than what was used in the 
previous inhibitor test. Similar to the setup of the previous test (described above), verapamil 
solution was added to the cell culture to achieve a final concentration of 100 µM. Verapamil was 
incubated with the cell cultures for 30 min and the paclitaxel solution was next added to achieve 
the final concentration of 50 mg/L. 1 mL media samples were taken at 5 min, 15 min, 30 min, 1 
hour, 6 hours and 24 hours. The same processing procedure was used to prepare the cell and media 
samples for paclitaxel quantification on the UPLC, except the media samples were not centrifuged 
before they were dried in the centrifugal evaporator in the first step.  
3.2.5 Statistical analysis 
 Two-way Anova and Student’s t-test were used to analyze the experimental data of the 
inhibitor test. Two-way Anova was used for the results of the first inhibitor test. It was used since 
there are two independent variables in the experimental setup: the inhibitor treatments and the time. 
The dependent variable is the concentration of paclitaxel. The purpose of the two-way Anova was 
to study the interaction between the independent variables and the dependent variable. Particularly, 
for the inhibitor test, two-way Anova was used to study the effect of inhibitors and incubation time 
on the paclitaxel concentration. The test was conducted by using Graphpad software. In the test 
setup, data were entered so that each row represent a time point, and the concentrations of 
paclitaxel at each time point from the same culture were in the same column. A sample data entry 
for the verapamil treatment and control group is shown in Figure 9. 
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Figure 9. Data entry of the two-way Anova test for the test results of media samples from verapamil treated cell 
culture and the cell culture without inhibitor treatment. Group A, B and C represent the cell culture with 50 µl of 
50µM, 100µM and nanopure water treatment. Y1, Y2 and Y3 represent three replicates of each treatment. 
 
A two-way Anova report is generated by the software. The setup window is shown in the Figure 
10. 
 
Figure 10. The setup window of a two-way Anova test in Graphpad  
 
In the report, the statistical significance of the effect of inhibitor treatment and time were reported. 
In the inhibitor test results, *=p<0.0332, **=p<0.0021, ***=p<0.0002 and ****=p<0.0001 as 
compared to the results of cell cure without treatment.  
Two-way Anova could only show the statistical significance between the variables. It 
cannot identify the particular interactions between the subgroups of variables that caused the 
statistically significant difference. For example, the test can only tell if the inhibitor treatment has 
significant effect on the concentration of paclitaxel, but it cannot show which concentration of 
inhibitor has the effect. To identify interactions within the subgroups, a Tukey’s multiple 
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comparison test was done for each treatment with the control group. Based on the test result, it 
could be determined if the change in paclitaxel concentration is significant by using inhibitor.  An 
example of the Tukey comparison setup is shown in Figure 11. 
 
Figure 11. The setup window of a Tukey’s multiple comparisons test 
 
For the experiment result of the inhibitor test for investigating effect of inhibitor 
concentrations, Student’s t-test was conducted for the data analysis. The t-test assumes unequal 
variances was used because there is only one independent variable, treatment of verapamil or not. 
To be able to do parallel comparison, the data of verapamil treatment group from the preliminary 
inhibitor test were also analyzed by the t-test. All the t-tests were conducted in Excel. In the test, 
a “*” indicates p<0.05. A sample of the t-test result is shown in Figure 12. 
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Figure 12. The setup window of a Student’s t-test in Excel 
 
3.3 Alternative method of paclitaxel quantification 
3.3.1 Literature review 
Concentrations of paclitaxel are typically quantified using UPLC. It is a technique that can 
be used to separate, identify and quantify the compound of interest in a mixture. Within the 
apparatus, compounds are separated by interacting differently with a column composed of solid 
absorbents. A pressurized liquid, also known as the “liquid phase”, is used to influence the 
interactions and to elute the compounds from the column. The concentrations of the separated 
compounds are analyzed by a UV/vis detector (53). A similar detector is also used in UV-vis 
Spectroscopy. The detector can measure the light absorption caused by the transition of electrons 
from ground state to an excited state in a particular molecular structure of the compound of interest. 
The strength of the absorbance would indicate the concentration of the compounds (54). Since 
UV-vis spectroscopy also uses a UV/vis detector to quantify the concentrations of compounds, 
these two machines are essentially using the same principle of quantification, which is Beer’s Law. 
Research has been done for the comparison of UV-vis spectroscopy and high performance liquid 
chromatography (HPLC), a less optimized version of UPLC. According to the test results, though 
the HPLC is more accurate than the UV-vis spectroscopy, both methods are reliable for the 
quantification of pharmaceutical formulations and UV-vis spectroscopy is the more economical 
testing option (55, 56). Therefore, in this project, UV-vis spectroscopy was hypothesized as a faster 
and cheaper alternative method for paclitaxel quantification. 
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3.3.2 Preliminary test of UPLC samples in UV-vis 
The preliminary tests were done by testing UPLC samples in the UV-vis spectroscopy, 
using water-acetonitrile solution as a blank. Since a peak at 230 nm is used to characterize 
paclitaxel, all absorbances were read at that wavelength (57). A pair of quartz cuvettes was used 
due to the low wavelength to avoid the interference of absorbance from another cuvette. The 
calibration curve of absorbance against paclitaxel concentrations was made through reading water-
acetonitrile samples with known paclitaxel concentrations. Since paclitaxel is added into the media 
instead of directly into water-acetonitrile solution, it is also necessary to obtain the standard curve 
for media based solution with known paclitaxel concentrations. Like the standard curve of 
paclitaxel in the pure water-acetonitrile solution, the standard curve for media based samples was 
obtained by testing a range of paclitaxel concentration from 10 mg/L to 70 mg/L. To prepare the 
media based samples, 1 mL media aliquots were obtained from the flasks of Taxus cell cultures at 
day 7, halfway through the cell transfer cycle, and paclitaxel-methanol solution was added to make 
the aliquots with different known concentrations of paclitaxel. The aliquots were dried in the 
centrifugal evaporator and resuspended in methanol and water-acetonitrile solutions following the 
identical procedure of UPLC samples processing described above. The aliquots were tested with 
UV-vis spectroscopy, using water-acetonitrile solution as a blank, and the absorbance at 230 nm 
was recorded. 
3.3.3 Identification of the interfering compound   
There are four main components in the media: Gamborg B5, sucrose, 6-benzylaminopurine 
(BA), and naphthaleneacetic acid (NAA). Based on the recipe of the media, 0.0321 g of Gamborg 
B5, 0.02 g of sucrose, 1.2 µl of BA, and 27 µl of NAA were dissolved in 10 mL nanopure water 
separately. The well mixed solutions were tested three times each with UV-vis spectroscopy using 
water as a blank. 
4. Results and discussion 
4.1 Bioinformatics analysis 
4.1.1 Identification of the homolog protein in Taxus cells  
According to the NCBI search results, a gene named E6Y0T0 in the Taxus 
cuspidata transcriptome was identified as a transport protein candidate. The protein sequence of 
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E6Y0T0 is 42.2% identical and 61.5% similar to that of ABCB4 (MDR3) protein, and 40.6% 
identical and 61.0% similar to that of ABCB1 (MDR1) protein. All the sequences are included in 
Appendix A and the alignment of all three sequences is included in Appendix B. Using 30% as the 
threshold for homolog protein identification, E6Y0T0 is considered as the homolog to the two 
MDR proteins in mammalian cells and therefore should have similar function as the two proteins. 
To support this idea, particular attention was paid to the alignment of the functional domains. As 
mentioned previously, MDR proteins belong to a subfamily of ABC protein. Their functional 
domains are, therefore, characterized as the ABC transporter domains. The alignment results are 
shown in Figure 13.  
  
A)  
B)  
Figure 13. The alignment of ABC transporter domains. A) transporter domain 1 and B) transporter domain 2. The 
darker gray or “*” in the figure indicate identical amino acid among the sequence, while the lighter gray or “:” and 
“.” indicate similar amino acids  
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When the sequence of the three proteins are aligned together at the specific domains, E6Y0T0 has 
54% identity and 88% similarity to the ABCB1 and ABCB4 sequences in the transporter domain 
1 and 53% identity and 85% similarity to the ABCB1 and ABCB4 sequences in the transporter 
domain 2. Comparing with the identity and similarity of the entire sequence, both percentages are 
higher when only the sequences of functional domains are compared. Overall, since the structure 
and function of a protein is highly dependent on it sequence, it is highly possible that the protein 
candidate, E6Y0T0, has similar functions as the mammalian MDR proteins that is responsible for 
paclitaxel efflux.    
4.1.2 Confirmation of the protein candidate in Taxus cell culture  
To conduct PCR of E6T0Y0 in the genome of current Taxus cell lines, 10 pairs of primers 
were designed and the best pair of primers was suggested by IDT. The forward primer is 5’ 
ACATGGCTAAGGCAAAGGACA 3’ and the backward primer is 5’ 
ACCCCCAGATAATTGCACCC 3’. PCR was done with this pair of primers and the Taq DNA 
polymerase. The electrophoresis gel results of the PCR reaction are shown in Figure 14.  
 
Figure 14. The electrophoresis results of PCR reactions using Taq DNA polymerase and the DNA extract 
of P093AF. The extension times were set to 4 min or 6 min for each PCR reaction. 
  
There are two distinct products from each PCR reaction (Figure 14). One is approximately 
1500 base pair (bp) and the other is approximately 300 bp. However, according to the mRNA 
sequence of E6Y0T0, the amplicons of the gene should be at least 3500 bp. There could be three 
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potential explanations for the smaller sizes of PCR products. First, the extension time could be too 
short so that the long sequence was not fully amplified during the reaction. Second, the polymerase 
might not be robust enough to build such an extensive sequence without falling off. Third, the 
primer sequence could be non-specific within the genome and random, shorter DNA segments 
were amplified. To test the possibility of using insufficient extension time, the PCR reaction was 
performed at 4 min and 6 min separately, while 6 min is two and half minutes more than the 
recommended extension time. However, the size of PCR products did not change when longer 
extension time was used (Figure 14). Therefore, the extension time was likely not the cause for the 
small PCR products. 
To further investigate the cause of the smaller PCR products, more comprehensive 
experiments were conducted. A more robust DNA polymerase, Q5, was used in parallel with Taq 
DNA polymerase. Genomic DNA was extracted from multiple Taxus cell lines and one 
Arabidopsis cell line (control) and used in the PCR with the designed primers (Figure 15).  
 
Figure 15. The electrophoresis results of PCR reactions using Taq and Q5 DNA polymerase and the DNA 
extract of all cell lines. Taq was used to amplified the DNA segments shown in the second lane from left to right. Q5 
was used to amplify the rest of DNA segment on the gel.  
Since a higher size of product will have stronger signal on the agarose gel as a brighter 
band, the strong signal of the products amplified by Q5 indicate it is a more robust DNA 
polymerase. However, all the products amplified by both DNA polymerases were smaller than 
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3000 bp. Thus, the smaller size of PCR reaction products is not likely caused by the low 
effectiveness of DNA polymerase. Moreover, the amplicons of the DNA from other Taxus cell 
lines and Arabidopsis cells had similar sizes, smaller than 3000 bp as well. The genomic DNA 
extract of Arabidopsis was included in this experiment as a negative control so we did not expect 
to see any band. A search of the primer sequences against the database of Arabidopsis genomic 
DNA sequence was performed through The Arabidopsis Information Resource (TAIR) prior to the 
experiment and no hit was found. In theory, the genomic DNA of Arabidopsis should not be 
amplified in PCR reaction. However, there were bands shown on the agarose gel, indicating DNA 
segments of Arabidopsis were amplified (Figure 15). Therefore, it is mostly likely that the primers 
that were used in all the reactions were non-specific. In other words, the primers can bind to 
undesired sections of genomic DNA in both Taxus and Arabidopsis cells. The binding affinity of 
the primers was strong enough for the DNA polymerase to start amplifying the undesired segments. 
There could be two reasons for the non-specific primer binding. First of all, the primer was 
designed based on the mRNA sequence instead of the DNA sequence of the E6Y0T0 protein. 
Since the sequence of mRNA does not include the introns in DNA and introns are a component of 
eukaryotic genomes, it is highly possible that the mRNA sequence of E6Y0T0 does not fully 
represent the entire DNA sequence of the protein. Moreover, the continuous segments of the 
mRNA sequences on which the design of primers were based could be separated by introns in the 
DNA sequence and undergo splicing post-transcriptionally. Consequently, the primers might not 
be able to precisely bind with the DNA at the desired location in the Taxus genome.  
The size of the target gene is close to the medium size of the common amplification size in 
the PCR reaction (0.1 to 10 kilo base pairs) (58). Since there are about 3500 bp nucleic acids that 
encode the protein structure in the mRNA sequence, the entire DNA sequence would be even 
larger when introns are considered. While the sequence is not fully known, the designated locations 
of primers’ binding sites could be farther from each other than expected due to the large size of 
the target gene. It is possible to have similar binding sites in between the two designate ones, for 
example, in the intron areas. Therefore, the binding of the primers could be less specific.   
More information about the genomic DNA sequence of this protein is needed to be able to 
confirm E6Y0T0 in the current cell cultures using PCR. Another alternative method would be 
using the technique of real time PCR (RT-PCR) to verify expression of the gene in the cell cultures.  
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4.2 Inhibition of active transport 
4.2.1 Cell viability test with the selected inhibitors 
 
Figure 16. Cell viability test results after 24 h and 48 h incubation. P093X cell line was used.  
 
After the first 24 hour incubation, all the cells with treatments are 100% alive (Figure 16). 
This is the comparable to the negative control result where cells were incubated without treatment. 
After the 48 hours of cells incubation, cells with verapamil, genistein and cyclosporine A showed 
a decrease in viability. However, the viability of the cultures was not lower than 85%. Therefore, 
the inhibitors, methanol, and DMSO did not have a significant effect on the viability within 48 
hours of incubation and they have no effect on cell viability for the first 24 hours of incubation. 
Therefore, the time interval selected for the experimental procedure of the inhibitor test was 24 
hours.  
4.2.2 Inhibitor test 
Verapamil, genistein, cyclosporine A and vanadate were used for the initial inhibitor test. 
For each inhibitor, two concentrations were tested. Cell culture with no addition and cells 
incubated with DMSO were the two controls in the experiment. All groups of cells were spiked 
with paclitaxel and cell culture and media samples were taken at four time points. The 
concentration of paclitaxel in the media or cell samples were tested in UPLC and results are shown 
in Figure 17. The results of statistical analysis are included Appendix D.  
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Figure 17. Results of inhibitor test: A) Paclitaxel concentration in cell-associated samples, B) Paclitaxel 
concentration in media samples. *=p<0.0332, **=p<0.0021, ***=p<0.0002 and ****=p<0.0001 as compare to 
control (cell+paclitaxel) according to two-way Anova and Tukey’s multiple comparisons test, N=3. The error bars 
represent the standard deviation of triplicates. 
 
In general, the paclitaxel concentrations in the cell samples increased over time, while the 
paclitaxel concentration in the media samples decreased over time. This trend suggests that 
paclitaxel has been taken up by the cells. The data for cells incubated with only DMSO was not 
shown since it is not statistically different from the results of the untreated cell culture indicating 
the two control groups were comparable and DMSO had no effect on paclitaxel transport. It was 
hypothesized that the inhibitors would inhibit the uptake of the paclitaxel so more paclitaxel would 
remain in the media. Also, higher inhibitor concentrations may have a more significant effect. 
However, other than the general trend showing paclitaxel uptake, concrete conclusions about 
paclitaxel transport mechanism cannot be made when taking the results of statistical analysis into 
consideration. In the media samples, the difference in concentrations of paclitaxel in each 
treatment group and control group was not statistically significant. This suggests that a 0.17 µM 
inhibitor solution does not affect the transport mechanism of paclitaxel within the system of study. 
When the cells were treated with higher concentrations of verapamil, cyclosporine A and genistein, 
the concentration of paclitaxel in the media is significantly lower than that of the control group 
after 6 hours. This result indicates a potential facilitation of uptake by the inhibitors. However, this 
potential facilitation is transient since the concentrations of paclitaxel in the inhibitor treated 
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groups were comparable with that in the control group after 24 hours incubation. The same result 
was observed, but earlier in the experiment, for the vanadate treated group. When a higher 
concentration of vanadate is added, the concentration of paclitaxel in the media is significant lower 
than the control group after 1.5 hours. However, paclitaxel concentrations are comparable with 
that of control group during the rest of the experiment. Therefore, the significant effects of 
inhibitors were transient and there was no consistent trend.  
According to the cell-associated samples, the inhibitors generally had an effect at lower 
concentrations. The paclitaxel concentration in verapamil and cyclosporine A treated groups was 
significantly lower than the control group after incubation for 6 hours, indicating potential 
inhibition of uptake. However, the paclitaxel concentration in the vanadate treated group was 
significantly higher than the control group, which could be a potential facilitation of uptake. 
Similar with the results seen for the media samples, the phenomena demonstrated in the cell-
associated samples was also transient and could not be observed at the next time point.  
Observations based on the cell-associated samples did not agree with observations based 
on media samples. This could be explained by errors in the experiment design. First, the amount 
of paclitaxel in the cell-associated samples are not normalized to the sample volumes, and a volume 
of 1 mL was assumed for each sample. During the experiment, 1 mL of cell samples were taken 
and processed for paclitaxel concentration analyses. However, since the sample was taken directly 
from the suspension culture, there was media in the cell samples, which was removed before 
sample processing. In other words, the actual volume of the cell samples was less than 1 mL, varies 
across the samples, and final cell volumes are unknown. Although triplicate biological samples 
had been run to reduce the effect of the variation in the final data, the cell volume could certainly 
affect the statistical analysis and make it hard to decipher a trend from the results.  
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Figure 18. Percent recovery of paclitaxel in the preliminary inhibitor test. The recovery percentages were 
obtained by calculating the total mass of paclitaxel recovered in media and cell samples and compared with the total 
mass of paclitaxel added into the culture at the beginning of the experiment. 
 
The highest percentage of paclitaxel recovery is 13.3 ± 6.2% among all the samples (Figure 
18). In other words, the majority of the paclitaxel was lost during the experiment and/or sample 
processing. There are two main reasons likely for the low recovery. One is the incorrect processing 
procedure for the media samples. During the sample processing, the media samples from cell 
culture were centrifuged and only the supernatant was obtained for the next process step. However, 
since paclitaxel is a hydrophobic molecule, it associates with suspended proteins, tissues or other 
cellular debris in the media. Once the media sample was centrifuged, the higher concentration of 
paclitaxel would more likely be in the pellet instead of the supernatant. Therefore, significant 
paclitaxel may have been lost at the beginning of the sample processing. Another possibility is 
overestimation of cell volume. Since the actual volume of each sample was unknown, the recovery 
was calculated based on 1 mL of cell sample. However, as mentioned previously, the actual volume 
of the cells was less than 1 mL in each sample once the media was removed. This overestimation 
of cell volume causes an underestimation of the paclitaxel recovery. Since the amount of 
unaccounted paclitaxel cannot be accurately determined for media or cell samples, variations were 
created and results could be affected. 
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4.2.3 Investigation of the effect of concentration on inhibition  
Among all the results given through the initial inhibitor test, the verapamil treated cells 
show the clearest trends in influencing paclitaxel transport. To further investigate inhibition of the 
paclitaxel transport mechanism, verapamil was evaluated at a higher concentration and samples 
were taken at more time points (Figure 19), 
A)  
B)  
 
Figure 19. A) Subset media sample data from the previous experiment with verapamil treatment, B) Paclitaxel 
concentration in media with increased concentration of verapamil *=p<0.05 as compare to control according to 
Student’s t-test, N=3. The error bars represent the standard deviation of triplicates. 
 
According to Figure 19A, when the final concentration of verapamil in the cell culture is 
0.17 µM or 0.33 µM, the concentration of paclitaxel in the media was lower than that in the control 
group after 24 hours. This indicates the verapamil treatment is facilitating the uptake of paclitaxel. 
However, when the final concentration of verapamil was 100 µM in the cell culture the 
concentration of paclitaxel in the media was higher than that in the control group (Figure 19B), 
indicating an inhibition of paclitaxel uptake by verapamil. Moreover, the facilitation of the uptake 
for 0.33 µM started after incubation for 6 hours, while the inhibition of 100 µM verapamil occurred 
after 24 hours of incubation. More tests are certainly needed to make concrete conclusions about 
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the correlation of the verapamil concentration and paclitaxel transport direction and the action time 
of the verapamil inhibition. However, these experiments indicate that that verapamil has an effect 
on paclitaxel transport, suggesting that a MDR-type protein may be involved.  
4.3Alternative paclitaxel quantification technique  
4.3.1 Establishing a paclitaxel concentration calibration curve with UV-vis technologies  
To investigate the potential of using UV-vis spectroscopy for paclitaxel concentration, 
media and cell samples that had been tested in UPLC were tested in UV-vis spectroscopy. The 
UV-vis spectra are shown in Figure 20. 
 
Figure 20. UV-vis spectra of UPLC media and cell samples. The red line represents the spectrum of cell sample and 
the black line represents the spectrum of media sample. 
 
As shown in Figure 20, a peak at 230 nm wavelength with absorbance around 1, is detected in the 
media sample. Since the peak at 230 nm is used to characterize paclitaxel, it is likely that the peak 
on the media UV-vis spectrum at that wavelength represents the paclitaxel in the media sample. 
This led us to believe that UV-vis could be an alternative method for paclitaxel quantification. It 
was also noticed that on the spectrum of the cell sample, there was no peak at 230 nm (Figure 20). 
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The lack of peak could be a result of several reasons including undetectable paclitaxel levels or 
the interference of absorption of paclitaxel by other cellular components. 
To further investigate development of a protocol to quantify paclitaxel with UV-vis, a 
calibration curve of absorbance against paclitaxel concentration was generated.  (Figure 21).  
 
Figure 21. Standard calibration curve of paclitaxel in water-acetonitrile solution 
 
According to Figure 21. there is a strong linear correlation of the absorbance and the 
paclitaxel concentrations within the range of 10 mg/L to 65 mg/L. The upper limit that can be 
tested is 70 mg/L since paclitaxel is not soluble in water-acetonitrile solution at higher 
concentrations. The lower limit was 10 mg/L because the paclitaxel peak is not distinguishable 
when concentrations below were tested. Overall, the linear calibration curve indicates that any 
concentration of paclitaxel in water-acetonitrile solution can be easily and accurately quantified 
within the range of 10 to 65 mg/L using the UV-vis.  
After seeing the promising correlation of the absorbance and paclitaxel concentration in 
pure water-acetonitrile solutions, the absorbance of paclitaxel was also tested in Taxus media-
based samples. As mentioned in the methodology, the media-based samples were processed using 
the same protocol for typical UPLC analyzed samples with different concentrations of paclitaxel 
in fresh media. The results are shown in Figure 22.    
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Figure 22. Absorbance of different concentrations of paclitaxel in media based solution in UV-vis spectroscopy 
 
As shown in Figure 22, the absorbance of media is independent of the paclitaxel 
concentration. Regardless of the concentration, the absorbance at 230 nm wavelength was around 
2. The strong absorbance in the spectra of media-based samples indicates that there are interfering 
component(s) in the fresh media that have the same absorbance as paclitaxel. 
4.3.2 Identification of the interfering compound(s) 
 There are four main components in the media: Gamborg B5, sucrose, 6-benzylaminopurine 
(BA), and naphthaleneacetic acid (NAA). Four of them were dissolved separately in the nanopore 
water at their appropriate media concentration and their UV-vis spectra were obtained (Figure 23).   
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Figure 23. UV-vis spectrum of A) sucrose B) Gamborg B5 salts C) BA D) NAA. Green, red, and black represent 
three different trials 
 
Gamborg B5 is the only media component that has a strong absorbance of 2.1 at 230 nm. 
The spectra of nanopure water and acetonitrile was also obtained, but no peak showed up at 230 
nm. Since Gamborg B5 is the only component showing a peak at 230 nm, and its absorbance is 
comparable with the results in the media-based sample tests, it is most likely the interfering 
component in the UV-vis test. Since it can be detected in both water-based samples and water-
acetonitrile-based sample after UPLC sample processing, Gamborg B5 must be soluble in all of 
the solvents used for extraction. Specifically, it is soluble in water, methanol and water-acetonitrile 
solutions. In fact, Gamborg B5 is a mixture of vitamins and minerals commonly used in the plant 
cell culture (59). As the interfering component in the test, Gamborg B5 is an essential element of 
the plant cell culture media and cannot be eliminated from the experimental setup. Therefore UV-
vis spectroscopy cannot be used as an alternative method for quantifying paclitaxel. 
5. Conclusion 
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Based on the experimental results, there are three major conclusions that can be made. First, 
in the bioinformatics analysis, the high percentage identity and similarity with mammalian MDR 
proteins, especially at the function domains suggested that E6Y0T0 is a potential transport protein 
of paclitaxel in Taxus cells. Second, in the inhibitor tests, it was shown that verapamil affects 
paclitaxel transport, supporting an MDR-like transport mechanism. Third, the investigation of an 
alternative paclitaxel quantification technique has shown that UV-vis spectroscopy cannot be used 
to test paclitaxel concentration with the current Taxus experimental setup.  
6. Future directions 
Future experiments should include isolating E6Y0T) and expressing it in Saccharomyces 
cerevisiae to determine its function and biochemical activity. If found indeed to be the paclitaxel 
transport protein, a genetically modified cell line overexpressing the transport protein could be 
developed to increase secretion to the media and improve recovery and purification of paclitaxel. 
Inhibitor tests should be repeated and expanded including optimizing concentrations and 
redesigning experimental protocols to enable a mass balance on the paclitaxel added to the cultures. 
All of these recommendations for future experiments should be implemented in order to fully 
characterize paclitaxel transport to optimize the downstream process of paclitaxel bioprocessing. 
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8. Appendix 
Appendix A: Protein Sequences  
Sequence of E6Y0T0 
>tr|E6Y0T0|E6Y0T0_TAXCU MDR-like ABC transporter OS=Taxus cuspidata GN=mdr 
PE=2 SV=1 
MPKEGDNSNDGNHDHGAVSLNIEKVSEMNSNMAKAKDKKKKENNKVVPFHKLFVTADSLD 
KLLMALGTIGAVANGVSIPLMTILFGGLINAFGENSTDGKKVMNEVSKLALEFVYLACGA 
GVASLLQVSCWMCTGERQATRIRSLYLKTILRQDIGFFDSEASTGEVIGRMSGDTILIQD 
AMGEKVGKFIQFITTFIAGFVIAFIKGWKLSLVMLSMIPLLVVSGGSMAMIISKMSSRGQ 
QAYSEAANIVEQTIGSIRMVASFTGEKKSIEGYNKSLAIAYNAITQQGLVAGVGLGSVLF 
IMFCGYALALWYGSRLILDGSYTGGDVINVIFAVLMGGMSLGQTSPSLNAFSAGRAAAYK 
MFETIDRKPVIDVFDKSGLVLEDIQGDIELKDVRFTYPARPDVQVFSGFSLEIPSGTTAA 
LVGESGSGKSTVISLVERFYDPQAGEVLIDGINIKKFQLKWIRQKIGLVSQEPVLFGTTI 
KENLLYGKDGATLEEIKAAAELANAAKFINKLPQGFDTMVGEHGTQLSGGQKQRIAIARA 
ILKDPRILLLDEATSALDTESERVVQEALDRIMVNRTTVIVAHRLTTVRNADMIAVVQRG 
SIVEKGSHSQLITNPSGAYSQLIHLQESNRSKEQDSKDPDELEIHQDDSKVLGRVSSQRS 
SFRRSISSGSSGIGGSRRSYSFSYAFPGTVGLQETGGMEEISQSKGNKRRKGLMSYFRSN 
TQKDVEGGQSDAEKDVSILRLASLNKPEIPVFILGSIAAAMNGMIFPVFGLLLSSVIKVF 
YEPPHELRKDAKFWALMFIVLAVTCFIVAPTQMYCFSIAGGRLVQRIRSLTFSKVVYQEI 
SWFDDNENSSGAISARLSTDAATVRSLVGDALSLVVQNIATIIAGIVISFTANWLLALLI 
LAIVPLLGLQGYMQVKFMTGFTADAKLVYEEASQVANDAVGSIRTVASFCAEDKVISLYN 
EKCSAPLKSGVKQGIIAGLGLGFSNFVMFTQYALSFWVGARLVEDGKTTFDKVFKVFFAL 
SMAAAGISQSAGLSPDLAKAKSSINSVFKILDRPSKIDANDESGTILDNVKGDIEFQHVS 
FKYPTRPDVQIFRDLCLFVHSGKTVALVGESGSGKSTAIALLERFYDPDSGRIFLDGVEI 
RQLQLKWLRQQMGLVSQEPVLFNDTIRANIAYGKEGAVTDEQIIAAAEAANAHKFISSLP 
QGYNINVGERGVQLSGGQKQRIAIARAILKDPRILLLDEATSALDAESERIVQDALDRVK 
VNRSTIVIAHRLSTIKDADLIAVVKNGKIAEQGKHDELLKKRNGAYASLVQLHKSS 
 
Sequence of ABCB1 
>sp|P08183|MDR1_HUMAN Multidrug resistance protein 1 OS=Homo sapiens GN=ABCB1 
PE=1 SV=3 
MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLYMVVGTLAAII 
HGAGLPLMMLVFGEMTDIFANAGNLEDLMSNITNRSDINDTGFFMNLEEDMTRYAYYYSG 
IGAGVLVAAYIQVSFWCLAAGRQIHKIRKQFFHAIMRQEIGWFDVHDVGELNTRLTDDVS 
KINEGIGDKIGMFFQSMATFFTGFIVGFTRGWKLTLVILAISPVLGLSAAVWAKILSSFT 
DKELLAYAKAGAVAEEVLAAIRTVIAFGGQKKELERYNKNLEEAKRIGIKKAITANISIG 
AAFLLIYASYALAFWYGTTLVLSGEYSIGQVLTVFFSVLIGAFSVGQASPSIEAFANARG 
AAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLEFRNVHFSYPSRKEVKILKGLNLKVQSG 
QTVALVGNSGCGKSTTVQLMQRLYDPTEGMVSVDGQDIRTINVRFLREIIGVVSQEPVLF 
ATTIAENIRYGRENVTMDEIEKAVKEANAYDFIMKLPHKFDTLVGERGAQLSGGQKQRIA 
IARALVRNPKILLLDEATSALDTESEAVVQVALDKARKGRTTIVIAHRLSTVRNADVIAG 
FDDGVIVEKGNHDELMKEKGIYFKLVTMQTAGNEVELENAADESKSEIDALEMSSNDSRS 
SLIRKRSTRRSVRGSQAQDRKLSTKEALDESIPPVSFWRIMKLNLTEWPYFVVGVFCAII 
NGGLQPAFAIIFSKIIGVFTRIDDPETKRQNSNLFSLLFLALGIISFITFFLQGFTFGKA 
GEILTKRLRYMVFRSMLRQDVSWFDDPKNTTGALTTRLANDAAQVKGAIGSRLAVITQNI 
ANLGTGIIISFIYGWQLTLLLLAIVPIIAIAGVVEMKMLSGQALKDKKELEGSGKIATEA 
IENFRTVVSLTQEQKFEHMYAQSLQVPYRNSLRKAHIFGITFSFTQAMMYFSYAGCFRFG 
AYLVAHKLMSFEDVLLVFSAVVFGAMAVGQVSSFAPDYAKAKISAAHIIMIIEKTPLIDS 
YSTEGLMPNTLEGNVTFGEVVFNYPTRPDIPVLQGLSLEVKKGQTLALVGSSGCGKSTVV 
QLLERFYDPLAGKVLLDGKEIKRLNVQWLRAHLGIVSQEPILFDCSIAENIAYGDNSRVV 
SQEEIVRAAKEANIHAFIESLPNKYSTKVGDKGTQLSGGQKQRIAIARALVRQPHILLLD 
EATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEHGTHQQL 
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LAQKGIYFSMVSVQAGTKRQ 
 
Sequence of ABCB4 
>sp|P21439|MDR3_HUMAN Phosphatidylcholine translocator ABCB4 OS=Homo sapiens 
GN=ABCB4 PE=1 SV=2 
MDLEAAKNGTAWRPTSAEGDFELGISSKQKRKKTKTVKMIGVLTLFRYSDWQDKLFMSLG 
TIMAIAHGSGLPLMMIVFGEMTDKFVDTAGNFSFPVNFSLSLLNPGKILEEEMTRYAYYY 
SGLGAGVLVAAYIQVSFWTLAAGRQIRKIRQKFFHAILRQEIGWFDINDTTELNTRLTDD 
ISKISEGIGDKVGMFFQAVATFFAGFIVGFIRGWKLTLVIMAISPILGLSAAVWAKILSA 
FSDKELAAYAKAGAVAEEALGAIRTVIAFGGQNKELERYQKHLENAKEIGIKKAISANIS 
MGIAFLLIYASYALAFWYGSTLVISKEYTIGNAMTVFFSILIGAFSVGQAAPCIDAFANA 
RGAAYVIFDIIDNNPKIDSFSERGHKPDSIKGNLEFNDVHFSYPSRANVKILKGLNLKVQ 
SGQTVALVGSSGCGKSTTVQLIQRLYDPDEGTINIDGQDIRNFNVNYLREIIGVVSQEPV 
LFSTTIAENICYGRGNVTMDEIKKAVKEANAYEFIMKLPQKFDTLVGERGAQLSGGQKQR 
IAIARALVRNPKILLLDEATSALDTESEAEVQAALDKAREGRTTIVIAHRLSTVRNADVI 
AGFEDGVIVEQGSHSELMKKEGVYFKLVNMQTSGSQIQSEEFELNDEKAATRMAPNGWKS 
RLFRHSTQKNLKNSQMCQKSLDVETDGLEANVPPVSFLKVLKLNKTEWPYFVVGTVCAIA 
NGGLQPAFSVIFSEIIAIFGPGDDAVKQQKCNIFSLIFLFLGIISFFTFFLQGFTFGKAG 
EILTRRLRSMAFKAMLRQDMSWFDDHKNSTGALSTRLATDAAQVQGATGTRLALIAQNIA 
NLGTGIIISFIYGWQLTLLLLAVVPIIAVSGIVEMKLLAGNAKRDKKELEAAGKIATEAI 
ENIRTVVSLTQERKFESMYVEKLYGPYRNSVQKAHIYGITFSISQAFMYFSYAGCFRFGA 
YLIVNGHMRFRDVILVFSAIVFGAVALGHASSFAPDYAKAKLSAAHLFMLFERQPLIDSY 
SEEGLKPDKFEGNITFNEVVFNYPTRANVPVLQGLSLEVKKGQTLALVGSSGCGKSTVVQ 
LLERFYDPLAGTVFVDFGFQLLDGQEAKKLNVQWLRAQLGIVSQEPILFDCSIAENIAYG 
DNSRVVSQDEIVSAAKAANIHPFIETLPHKYETRVGDKGTQLSGGQKQRIAIARALIRQP 
QILLLDEATSALDTESEKVVQEALDKAREGRTCIVIAHRLSTIQNADLIVVFQNGRVKEH 
GTHQQLLAQKGIYFSMVSVQAGTQNL 
 
Appendix B: Alignment of the protein sequences 
 
43 
 
 
44 
 
 
  
Appendix C: mRNA sequence of E6Y0T0 
 
>ENA|DQ660357|DQ660357.1 Taxus cuspidata MDR-like ABC transporter (mdr) mRNA, 
complete cds.  
GAGGCTGTCCTCATCTGCTGCGTTTTTGCAGAAAGAGTTTGGCCATTTTTTCTGTAGAAA 
CTGATTCTTTCGGAGAAGTATTCGAGGAACATTGAATTTTCACTTGGAAATATTGACAGA 
AATAGTGACTTTCGCCGATAATTTTTGATCTTTTCAACGAAGCTGGTGGAAGACTGACTT 
TTAGATTGTTGCAGTGTTTTACGAGCAATTGCGTACAGACTTCGTCGAAATCTTTGCAGG 
GGTGTTGAATAACTGATTATTCCCATTGGAGTGCCACAGTTTTCTCAAGGGAGTAGTTCC 
ATCCCTGAAATCCGATATGCCAAAGGAAGGTGACAATTCCAATGATGGTAATCATGACCA 
TGGTGCAGTATCTTTGAACATTGAGAAGGTTTCTGAAATGAACTCAAACATGGCTAAGGC 
AAAGGACAAGAAAAAAAAAGAGAACAATAAGGTCGTGCCATTTCACAAATTATTTGTCAC 
GGCAGACTCTCTGGATAAATTGTTGATGGCTCTTGGTACTATTGGTGCTGTGGCCAACGG 
CGTATCTATTCCACTTATGACCATCCTGTTTGGGGGCCTTATAAATGCATTCGGGGAGAA 
CAGCACAGACGGGAAAAAAGTGATGAATGAAGTGTCCAAGCTGGCTTTGGAGTTTGTTTA 
TCTTGCCTGTGGTGCAGGAGTTGCAAGTTTACTTCAGGTGTCATGTTGGATGTGCACTGG 
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GGAAAGACAAGCTACACGCATCAGGAGTCTCTACCTAAAAACTATTTTGAGGCAAGATAT 
TGGATTCTTTGATAGCGAGGCATCGACAGGAGAGGTTATTGGAAGGATGTCGGGCGACAC 
CATATTAATTCAGGACGCCATGGGAGAAAAGGTTGGAAAGTTCATACAGTTCATAACCAC 
ATTCATAGCAGGATTTGTTATAGCTTTCATCAAAGGTTGGAAACTTTCCCTGGTAATGCT 
ATCCATGATTCCTCTTCTCGTTGTATCTGGCGGCTCGATGGCTATGATAATCTCCAAAAT 
GTCAAGCCGAGGCCAGCAAGCTTATTCAGAAGCAGCCAATATTGTGGAGCAGACAATCGG 
TTCAATTAGGATGGTTGCATCTTTTACTGGGGAAAAGAAATCCATAGAAGGTTATAACAA 
GTCACTTGCGATAGCTTACAATGCTATCACTCAGCAAGGGTTGGTAGCTGGTGTTGGCCT 
TGGGTCTGTTCTCTTTATCATGTTCTGTGGCTATGCATTGGCTCTTTGGTATGGATCACG 
GTTAATTCTAGATGGAAGTTATACCGGTGGCGATGTGATCAATGTCATATTTGCAGTTCT 
GATGGGAGGCATGTCTCTGGGCCAGACATCACCATCATTAAATGCTTTTTCAGCTGGACG 
AGCTGCAGCATACAAAATGTTTGAGACTATTGACAGAAAACCAGTGATTGATGTCTTTGA 
TAAATCTGGACTGGTCCTCGAGGATATTCAAGGTGATATTGAGCTTAAAGATGTACGGTT 
CACGTATCCTGCTAGACCAGATGTTCAAGTCTTTTCTGGCTTTTCACTAGAAATACCTAG 
CGGCACCACTGCAGCTTTAGTTGGAGAGAGTGGCAGTGGAAAGTCCACTGTTATCAGTCT 
TGTAGAGAGATTCTATGATCCGCAAGCTGGCGAAGTGCTTATTGATGGCATTAACATCAA 
GAAATTTCAGCTTAAGTGGATAAGGCAGAAAATTGGACTGGTGAGCCAGGAACCTGTTCT 
TTTTGGTACCACCATTAAAGAGAACCTTTTATATGGTAAAGATGGAGCTACATTAGAGGA 
AATCAAGGCTGCTGCTGAACTCGCCAATGCAGCAAAGTTTATAAACAAGTTGCCCCAGGG 
TTTTGATACAATGGTGGGAGAGCATGGTACCCAACTATCTGGAGGTCAAAAACAAAGAAT 
TGCAATTGCACGGGCTATTCTAAAAGATCCCCGAATTCTTCTCCTCGATGAAGCAACAAG 
TGCATTGGATACAGAATCTGAAAGAGTTGTTCAAGAAGCCCTTGACAGGATTATGGTAAA 
TAGAACAACAGTGATTGTTGCCCATCGTCTAACAACTGTCAGAAATGCTGACATGATTGC 
TGTTGTCCAGCGTGGTTCAATTGTGGAAAAAGGTTCTCACTCTCAGCTTATCACAAACCC 
TTCTGGTGCATACTCCCAGCTTATACATCTGCAAGAATCGAATCGATCAAAAGAACAAGA 
TTCAAAGGATCCAGATGAATTGGAAATACATCAGGATGATAGCAAGGTTCTTGGTAGAGT 
TAGCAGTCAAAGGTCATCTTTTAGACGGTCCATAAGCAGTGGATCATCAGGAATTGGTGG 
AAGTCGTCGTTCATATTCATTTTCTTATGCTTTTCCTGGTACAGTAGGCCTCCAGGAAAC 
TGGAGGTATGGAGGAAATCAGCCAATCAAAGGGAAACAAAAGAAGGAAGGGCCTGATGAG 
TTATTTTAGGTCCAATACTCAGAAAGATGTGGAAGGTGGTCAATCTGATGCTGAGAAAGA 
TGTTTCTATTTTACGTCTAGCATCTCTAAATAAGCCAGAGATTCCAGTGTTCATACTTGG 
ATCAATTGCAGCAGCTATGAATGGGATGATATTTCCCGTCTTTGGTCTCTTGCTTTCAAG 
TGTTATCAAGGTCTTCTATGAACCCCCTCATGAACTTCGAAAAGATGCCAAATTCTGGGC 
ACTTATGTTTATAGTTTTGGCAGTTACGTGCTTCATTGTGGCACCTACACAGATGTATTG 
TTTTTCCATAGCCGGTGGCAGGCTAGTGCAACGTATTCGATCGTTGACATTTTCCAAAGT 
AGTTTACCAGGAGATTAGCTGGTTTGATGACAATGAAAACTCAAGCGGTGCAATAAGTGC 
AAGATTATCAACAGATGCTGCAACTGTGCGTAGTTTGGTGGGAGATGCACTGTCACTTGT 
TGTTCAAAATATAGCAACCATCATTGCTGGCATTGTCATATCTTTTACGGCCAACTGGTT 
GCTAGCGCTTTTGATACTAGCTATAGTACCTCTTCTAGGTCTTCAAGGGTACATGCAAGT 
AAAGTTCATGACGGGTTTCACTGCTGATGCAAAGTTGGTGTATGAGGAAGCCAGTCAAGT 
TGCAAATGATGCTGTTGGAAGTATTCGAACTGTCGCCTCCTTCTGTGCAGAGGATAAGGT 
TATCAGTCTCTACAATGAAAAATGCTCTGCTCCCTTGAAAAGTGGAGTTAAACAGGGAAT 
TATAGCTGGACTTGGTTTAGGATTCTCAAATTTTGTGATGTTTACTCAATATGCACTCAG 
CTTTTGGGTAGGGGCTCGCTTGGTTGAAGACGGAAAGACAACTTTTGATAAAGTTTTCAA 
GGTGTTTTTTGCCCTCTCAATGGCTGCCGCGGGAATCTCTCAATCAGCAGGCCTTTCCCC 
TGACCTTGCAAAAGCCAAGTCCTCTATCAATTCAGTGTTCAAAATTCTTGACCGTCCTTC 
CAAGATCGACGCAAATGACGAGTCTGGGACTATCTTAGATAATGTGAAGGGTGACATTGA 
GTTTCAGCATGTCAGCTTTAAATATCCAACTCGTCCAGATGTGCAAATCTTCCGTGATCT 
ATGTTTATTTGTCCATTCTGGGAAGACTGTTGCTCTTGTGGGAGAGAGCGGAAGTGGTAA 
ATCAACAGCCATTGCTCTTTTGGAGCGATTCTATGATCCTGATTCAGGCCGTATATTCCT 
TGATGGAGTTGAAATTCGTCAACTTCAACTTAAATGGTTGCGACAACAGATGGGCTTGGT 
GAGCCAAGAGCCTGTTTTGTTCAATGATACAATCCGTGCAAATATTGCTTATGGAAAGGA 
GGGTGCAGTTACTGATGAGCAAATCATAGCAGCTGCTGAGGCTGCCAATGCCCACAAGTT 
CATATCAAGCCTTCCCCAAGGATACAACATAAATGTTGGCGAGCGAGGGGTGCAATTATC 
TGGGGGTCAAAAGCAACGCATTGCAATCGCAAGAGCAATACTAAAAGATCCCAGGATACT 
TCTCTTGGATGAAGCTACAAGTGCCCTAGATGCTGAATCAGAGCGCATAGTTCAAGATGC 
ATTGGACCGTGTAAAGGTAAACAGGTCTACTATTGTCATTGCTCACCGTCTTTCAACAAT 
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TAAAGATGCAGATCTCATAGCAGTGGTGAAGAATGGAAAAATTGCAGAACAAGGAAAGCA 
TGATGAATTGCTGAAGAAGCGAAATGGAGCCTATGCATCCCTAGTGCAATTGCATAAGTC 
CTCATAGTTTATTTTTCTGGAAATACAGAAATTTGTCTAGTGTGTATTTCATGCACATTG 
CTAGTAAAAAAATACTGGCAGGCAACAAAGTTAAGTTGCTATTGGTATCTTTCTAGGTCC 
ATAATATACAGTTGAAACAGCCAACAAAATGAATTGCTGTACTTTTATGTGGGAATAAAT 
TATTTAATTTGGGGACCAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
 
Appendix D: Statistic analysis results 
Two-way Anova test results 
Results of media samples with verapamil treatment  
 
Results of media samples with genistein treatment  
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Results of media samples with cyclosporine A treatment  
 
Results of media samples with vanadate treatment  
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Results of cell samples with verapamil treatment  
 
Results of cell samples with genistein treatment  
49 
 
 
Results of cell samples with cyclosporine A treatment 
 
Results of cell samples with vanadate treatment  
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Tukey’s multiple comparison results 
Results of media samples with verapamil treatment  
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Results of media samples with genistein treatment  
 
52 
 
 
Results of media samples with cyclosporine A treatment  
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Results of media samples with vanadate treatment  
 
54 
 
 
Results of cell samples with verapamil treatment  
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Results of cell samples with genistein treatment  
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Results of cell samples with cyclosporine A treatment 
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Results of cell samples with vanadate treatment  
 
 
Student’s t-test results 
Results of the verapamil treated groups in preliminary inhibitor test 
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Results of test with higher verapamil concentration after 24 hours incubation 
59 
 
 
 
 
